ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
Shuo Ma(Nantong University), Andrew W. Roberts(The Royal Melbourne Hospital), Nikita Rudersdorf(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), Mark C. Lanasa(Duke Medical Center), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Jacqueline C. Barrientos(Mount Sinai Medical Center), Tanita Mason-Bright(AbbVie (United States)), Wijith Munasinghe(AbbVie (United States)), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Jianning Yang(AbbVie (United States)), Sari H. Enschede(AbbVie (United States))
Cited by 22
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k